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Abstract
Background: Genetic studies have demonstrated a strong association between single nucleotide polymorphisms (SNPs) at
IL28B and response to treatment with peginterferon (PEG) and ribavirin (RBV) in HCV monoinfected persons. We sought to
test these associations in a prospective PEG / weight based ribavirin (WBR) treatment trial (ACTG A5178) (National Institution
of Health registration number NCT00078403) in persons with HCV-HIV coinfection, and to develop a prediction score.
Methods: We selected subjects enrolled in A5178 who completed at least the first 12 weeks of the trial and had DNA
available, and genotyped three SNPs at IL28B (rs12979860, rs12980275, rs8099917). We used multivariate logistic regression
analysis to evaluate the association between IL28B SNPs and HCV treatment outcomes and to develop the prediction score.
Results: 231 HCV/HIV coinfected subjects were included. We observed a strong association between IL28B genotype and
response to therapy among those with genotypes 1 or 4 (odds ratio for complete early virologic responses (cEVR) and
sustained virologic response (SVR) was 2.98 [1.7–5.3] and 3.4 [1.7–6.9], respectively, for each additional copy of the C allele of
rs12979860). Differences in frequency of the responder allele explained some of the discrepancy in HCV treatment
outcomes between blacks and whites. A simple pretreatment prediction score that incorporates the IL28B genotype and
baseline HCV viral load has a 93% negative predictive value (NPV) for SVR.
Conclusions: IL28B SNPs have an additive allele dose effect in predicting HCV treatment outcomes in HCV/HIV coinfected
persons and can be incorporated into a simple pretreatment prediction score that could minimize the risk of exposure to
PEG/RBV therapy for persons with unfavorable scores.
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Introduction
Hepatitis C virus (HCV) coinfection occurs in about one third of
subjects infected with the human immunodeficiency virus (HIV) in
the United States and Europe, owing to similarities in viral
acquisition risk factors and chronic persistence in the majority of
hosts.[1,2] Since the introduction of highly active antiretroviral
therapy (HAART) and the extended survival of persons infected
with HIV, the burden of HCV in coinfected persons is now fully
realized, with HCV emerging as the leading non-AIDS cause of
death. [3,4,5,6]
Another complicating factor is that liver fibrosis progression is
accelerated in coinfected persons, and response to pegylated
interferon (PEG) and ribavirin (RBV) treatment is generally poor
compared with HCV monoinfected persons. [7,8] Sustained
virological response rates (SVR) in coinfected persons have ranged
from 27%–40%. [9,10,11] Potential drug interactions with
HAART, higher rates of serious side effects, high cost, and poor
adherence to therapy have been some of the factors explaining
poor HCV treatment outcomes in coinfection. [2] To that end,
pretreatment algorithms that are able to segregate coinfected
subjects based on likelihood of response to this potentially harmful
and expensive therapy with limited efficacy are greatly needed.
Several studies have examined viral and host factors predicting
HCV virologic response in both HCV monoinfected and HIV
coinfected cohorts. Significant HCV factors associated with
favorable outcome include viral genotypes 2 and 3 and low
baseline HCV viral load. [12] Host factors associated with
favorable outcome in some studies include young age, female
gender, European descent (ethnicity), absence of advanced fibrosis
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by rapid virologic (RVR) and early virologic responses (EVR),
defined as clearance of HCV RNA by week 4 and reduction of
HCV RNA by at least 100-fold or clearance by week 12,
respectively. [12,13,14]
Recent genome-wide association studies (GWAS) have shown a
striking association between single nucleotide polymorphisms
(SNPs) around the IL28B gene (specifically, rs12979860,
rs8099917, and rs12980275) and response to PEG/RBV HCV
treatment.[15,16,17] IL28B encodes the type III interferon IFN-
l3, which belongs to the IFN-l family, which itself has potent
antiviral activity.[18,19]
Since the original reports, many studies have confirmed these
associations in both mono- and co-infected cohorts. [20,21,
22,23,24,25,26,27,28,29] Common limitations of studies of
HCV/HIV coinfected cohorts, however, have been their retro-
spective nature and lack of ethnic diversity. Therefore, we sought to
clarify the association between IL28B SNPs and response to PEG/
RBV treatment in the prospective multiethnic Sustained Long-
Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected
Patients (SLAM-C) cohort.[30] Furthermore, we developed a
pretreatment prediction score to identify subjects with low
probability to respond to peg-IFN based therapy, to minimize their
unnecessary exposure to potentially harmful therapy.
Methods
Study design
A5178 was a multicenter prospective, randomized, open-label,
controlled trial (National Institute of Health Registration number
NCT00078403) funded by the National Institute of Allergy and
Infectious Diseases (NIAID) and conducted by the AIDS Clinical
Trials Group (ACTG) to elucidate the role of maintenance PEG
therapy in HCV treatment non-responders with HIV coinfec-
tion.[30] The trial enrolled 330 subjects from August 2004 to April
2007 from 36 ACTG sites within the United States and the results
of the main study have been published. [30]
A5178 included subjects coinfected with HCV (genotypes 1, 2,
3, 4) and HIV-1, who were at least 18 years old, with HIV viral
load less than 50,000 copies/mL, and a CD4 count of at least 200
cells/mm
3. All subjects had detectable HCV RNA, at least stage 1
liver fibrosis on a biopsy performed within 2 years prior to study
initiation. Subjects could be either HCV treatment naive or
experienced. Those with history of AIDS-defining opportunistic
infections, decompensated liver disease, other liver diseases
(hepatitis B, acute hepatitis A, hemochromatosis, or homozygotic
alpha-1 antitrypsin deficiency), recent steroid use, active drug/
alcohol abuse, uncontrolled seizure disorders, uncontrolled active
depression, history of autoimmune disease, or history of major
organ transplantation were excluded.
The trial was conducted in three steps. In Step 1, all subjects
were treated with PEG-IFN alfa 2a (PEG) 180 mcg SQ per week
plus weight based RBV (WBR) for 12 weeks to separate treatment
responders from non-responders by EVR (defined as either at least
a 100-fold decrease or undetectable HCV RNA [,600 IU/mL] at
12 weeks). Non-responders entered Step 2 (the main trial) and
were randomized to 72 additional weeks of maintenance therapy
or to observation with no treatment. Responders entered a single-
arm study (Step 3) and received a total of 72 weeks of PEG and
WBR therapy.
For this study, we included all subjects who completed at least
Step 1 of ACTG A5178, consented for genetic testing prior to trial
entry[30], and had DNA available for IL28B genotyping. Thus,
out of 297 subjects completing Step 1, 231 were included in this
study. SVR was assessed 24 weeks after treatment cessation in step
3. None of those who entered step 2 achieved SVR.
Clinical assessments and outcomes measurement
Study visits occurred at weeks 2, 4, 8, and 12 in the first step of
the trial, and at weeks 2, 4,8,12, 16, 24, 32, 40, 48, 56, 64, and 72
in steps 2 and 3 to monitor adherence and perform routine safety
clinical and laboratory assessment. HCV RNA was tested using
the Roche Cobas Amplicor assay with a lower detection limit of
600 IU/mL for the quantitative assay (used in Step 1) and 60 IU/
mL for the qualitative assay (used in Steps 2 and 3). HIV RNA was
tested at using Roche Ultrasensitive HIV reverse transcriptase–
polymerase chain reaction with a lower limit of quantification of
50 copies/mL. Complete EVR (cEVR) was defined as HCV RNA
,600 IU/mL at treatment week 12 using the quantitative assay in
Step 1. SVR was defined as complete HCV clearance at 24 weeks
after treatment cessation.
IL28B genotyping
Baseline whole blood samples were used for genotyping. We
genotyped three SNPs surrounding IL28B most strongly associated
with response to therapy in the original genome-wide study [15]
(rs12979860, rs8099917, and rs12980275) using the iPlex
Sequenom platform at the Broad Institute. We obtained a call
rate of 97.8% for all three SNPs in our samples. In all ethnic
groups, none of the SNPs were out of Hardy-Weinberg
equilibrium (P.0.001).
Ethics statement
The A5178 clinical protocol was reviewed and approved by
National Institute of Allergy and Infectious Diseases and Food and
Drug Administration. All A5178 subjects provided written
informed consent. The A5178 protocol and written informed
consent was approved by the institutional review boards (IRB) at
all participating clinical sites (See supporting information for a full
list of participating clinic sites) [30] Subject enrolled in this
ancillary study provided written informed consent for genetic
testing at recruitment to A5178. This ancillary study was exempt
from IRB approval requirement by the Massachusetts General
Hospital IRB and was approved by the Broad Institute of MIT
and Harvard IRB.
Statistical Analysis
We performed multivariate logistic regression analysis to test the
association between IL28B SNPs and cEVR and SVR among
subjects with HCV genotypes 1 or 4. Fisher’s exact test was used to
assess for a statistically significant difference in the proportion of
subjects with HCV genotypes 2 or 3 achieving cEVR and SVR in
the different IL28B genotype groups.
We used logistic regression to develop a prediction score for
cEVR and SVR among those with HCV genotypes 1 and 4. We
converted continuous variables to ordinal and recoded them so
that the higher category predicted cEVR and SVR. We then used
forward selection to include variables significantly associated
(p,0.05) with these outcomes in a multivariate logistic regression
model. Two variables were included (IL28B genotype [three
categories] and base-line HCV viral load [three categories]). We
then converted the odds ratio estimates of these variables into a
point system based on their strength of association with cEVR and
SVR and calculated the area under the receiver operating
characteristic (ROC) curve for this prediction score. A cut-off
score #3 was chosen, as it maximized the negative predictive
value (NPV) for achieving cEVR and SVR.
IL28B and HCV Treatment in HIV
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fit of the predictive models. Statistical significance was set at a two-
sided p-value #0.05. All statistical analyses were done using SAS
version 9.2 software (Cary, NC, USA).
Results
IL28B and response to HCV treatment in the HCV/HIV
coinfected cohort
Among 231 HCV/HIV coinfected subjects included in this
study (baseline characteristics are shown in Table 1), 197 had
HCV genotypes 1 or 4 and 34 had genotypes 2 or 3. Complete
EVR (cEVR) and SVR rates among those with genotypes 1 or 4
were 36.5% and 30% respectively. In contrast, cEVR and SVR
rates among those with genotypes 2 or 3 were 94%, and 70%
respectively. We observed a strong association between IL28B
genotype and response to therapy among those with genotypes 1
or 4 (Table 2). The odds ratios for cEVR and SVR were 2.98 [1.7–
5.3] and 3.4 [1.7–6.9], respectively, with each additional copy of
the C allele of rs12979860 (Figure 1). The association between
IL28B genotype and response to PEG and WBR treatment in this
coinfected cohort was independent of age, sex, ethnicity, baseline
HCV viral load, or cirrhosis as shown in the multivariate logistic
regression model presented in Table 2. In this model both the
baseline HCV viral load and IL28B genotype emerged as strong
and independent predictors of response to PEG/RBV treatment.
Furthermore, when adjusting for all three SNPs in a multivariate
logistic regression model (model not shown), only rs12979860 was
associated with response to HCV treatment, consistent with these
SNPs all being in strong linkage disequilibrium with each other.
A statistically significant association between IL28B genotype
and response to HCV treatment was not observed among subjects
with genotypes 2 or 3 (Table 3a), nor was the responder
rs12979860 CC genotype overrepresented in those subjects
(Table 3b). A statistically non-significant trend for higher SVR
was observed among those with the rs12979860 CC genotype vs.
CT/TT (80% vs. 65%) (P=0.67) (Table 3a). However, the
number of subjects with genotypes 2/3 included in our study was
likely too small (n=34) to permit definitive conclusions.
Ethnic differences in IL28B distribution and response to
HCV treatment in the HCV/HIV coinfected cohort
Table 4 shows the ethnic distribution of the three IL28B SNPs
among HCV-HIV coinfected subjects. The responder genotype
CC at the rs12979860 locus had a lower frequency among black
subjects (17%) as compared to whites (45%) and Hispanics (26%).
These ethnic differences were less pronounced for the rs8099917
and rs12980275 SNPs.
Response to PEG and WBR treatment was also lower among
black HCV/HIV coinfected subjects as compared to whites with
odds ratio of achieving SVR of 0.5 [0.26–0.97] (Table 5).
Significant proportions of the lower response rates among blacks
were attributed to differences in the distribution of the IL28B
responder allele at the rs12979860 locus among blacks. Indeed,
after adjusting for IL28B genotype (rs12979860), the odds ratio for
SVR among blacks compared to whites were 0.68 [0.33–1.4]
(Table 5).
Pretreatment prediction score of the response to PEG/
WBR treatment
Given the independently strong association between IL28B
genotype, baseline HCV viral load, and response to PEG/WBR,
we sought to incorporate these variables into a pretreatment
Table 1. Baseline Characteristics of 231 subjects included in
our study.
Age (years) 47 (SD, 6.9)
Gender (%)
M 83%
F 17%
Ethnicity (%)
White 45%
Black 35%
Hispanic 16%
Other 4%
HCV Genotype (%)
1 81%
2 10%
3 5%
4 4%
HCV baseline viral load (IU/mL) 4,040,000 [IQR 1,580,000–8,880,000]
HIV baseline viral load (%
undetectable)
75%
CD4 count at baseline 591 (SD, 308)
Cirrhotic (%) 14%
Previous interferon experience (%) 35%
doi:10.1371/journal.pone.0025753.t001
Table 2. Multivariate logistic regression model for cEVR and
SVR among HCV/HIV coinfected subjects with HCV genotypes
1o r4 .
Complete EVR
Odds Ratio [95% CI]*
SVR
Odds Ratio [95% CI]*
Age
Years 0.96 [0.91–1.01] 0.94 [0.88–1.0]
Sex
Male vs. Female 4.1 [1.34–12.4] 3.6 [0.92–14.5]
Ethnicity
Black vs. White 0.78 [0.35–1.73] 1.38 [0.53–3.6]
Other vs. White 0.55 [0.2–1.5] 0.75 [0.22–2.61]
HCV RNA IU/mL
(baseline) 0.34 [0.18–0.62] 0.32 [0.16–0.64]
(log transformed)
Cirrhosis
(Metavir 4 or Ishak 5/6) 0.26 [0.1–0.8] 0.82 [0.25–2.66]
rs12979860
(per C allele) 2.98 [1.7–5.3] 3.4 [1.7–6.9]
rs129802751
(per A allele)
2.3 [1.36–3.88] 2.47 [1.35–4.54]
rs80999171
(per T allele)
2.7 [1.4–5.21] 2.28 [1.05–4.95]
*All ORs are adjusted for age, sex, ethnicity, baseline HCV viral load, cirrhosis,
and IL28B individual SNPs (either rs12979860 / rs12980275 / or rs8099917, but
not each other).
1Adjusted for the same covariates as rs12979860, but only the adjusted ORs for
these SNPs presented.
doi:10.1371/journal.pone.0025753.t002
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they may minimize unnecessary exposure to potentially harmful
therapy.
To construct this prediction score, we calculated the area under
the ROC for prediction of cEVR and SVR from a model that
included IL28B genotype (rs12979860) and pretreatment HCV
viral load. The area under the ROC for cEVR and SVR was 0.74
and 0.78 respectively (Hosmer–Lemeshow goodness-of-fit test, 0.6
and 0.92) (Figure 2). We then converted odds ratio estimates of
these predictors to a simple 12-point system based on their
strength of association with cEVR and SVR. The pretreatment
NPV for achieving cEVR and SVR for a cut-off score of #3 was
88% and 93%, respectively (Table 6).
This prediction score identified 67 coinfected SLAM-C subjects
with low likelihood to respond to PEG/WBR HCV treatment
(NPV for SVR 93%). Figure 3 shows a proposed pre HCV
treatment decision tree utilizing our prediction score and how it
applied to our HCV/HIV coinfected cohort.
Figure 1. Bar graph showing percent of subjects with different IL28B SNPs achieving SVR stratified by ethnicity.
doi:10.1371/journal.pone.0025753.g001
Table 3. IL28B among HCV/HIV coinfected subjects with HCV
genotypes 2 or 3.
A) Complete EVR and SVR rates among subjects with genotypes 2 or 3
rs12979860 cEVR SVR
CC 12/12(100%) 8/10(80%)
CT + TT 20/22 (91%) 13/20(65%)
B) Distribution of IL28B rs12979860 genotype in subjects with HCV
genotypes 2 or 3 compared to 1or 4
rs12979860 Genotype 2 and 3
(n=34)
Genotype 1 and 4
(n=186)
CC 12 (35%) 60 (32%)
CT + TT 22 (65%) 126 (68%)
doi:10.1371/journal.pone.0025753.t003
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Since the striking association between SNPs on chromosome 19
surrounding the IL28B gene and response to PEG/WBR were
reported, multiple confirmatory studies have replicated these
findings in cohorts with different racial backgrounds and extended
them to subjects with HCV/HIV coinfection. [15,16,17,24,
25,26,28] Common limitations to some of these studies were their
retrospective nature, which made them susceptible to selection
bias and less stringent outcomes ascertainment, and lack of ethnic
diversity. [24,25,26,28] In this study we confirmed the association
between SNPs surrounding the IL28B gene and response to HCV
treatment in a prospective multicenter study of HCV/HIV
coinfected subjects with different ethnic backgrounds and in
whom EVR, cEVR, and SVR were prospectively ascertained in
the context of the ACTG A5178 clinical trial.[30] Furthermore,
we showed that ethnic differences in the distribution of the IL28B
SNPs exist between black and white subjects. These differences
explain some of the poor PEG/WBR response rates in black
coinfected subjects compared to whites.
Contrary to reports from other HCV/HIV coinfected cohorts
[24,25,26], our study showed that the association between IL28B
alleles and HCV treatment outcomes is largely additive, where
subjects heterozygous for the responder IL28B alleles had
intermediate HCV treatment success rates compared to those
who are homozygote or did not possess a copy of these alleles. A
similar trend was recently reported by another study of an HCV
monoinfected cohort with advanced liver fibrosis. [21] In addition,
a recent study by Dill and colleagues showed that hepatic
expression of IL28B is decreased in the non-responder
(rs12979860) TT genotype as compared to CT or CC [31], a
finding previously suggested by another group in peripheral blood.
[17] Furthermore, Dill and colleagues showed that differences in
interferon stimulated gene (ISGs) expression between those with
CT and CC genotypes disappeared after stratification by PEG/
WBR treatment response, leading them to conclude that
differences in ISG between IL28B alleles shown by other groups
in unstratified analyses were likely due to unequal assignment of
non-responders to the heterozygote IL28B group. [32,33,34]
Although these findings need to be confirmed, they argue that
quantification of hepatic ISG expression is a better predictor of
SVR among subjects heterozygous for the IL28B allele. However,
this is not a practical approach in routine clinical practice.
The IL28B gene encodes IFN-l3, which along with IFN-l1 and
IFN-l2 constitute the type III interferons. HCV RNA in
hepatocytes is sensed by pattern recognition receptors, which in
turn induce expression of IFN-l, from both plasmacytoid dendritic
cells and hepatocytes. When these interferons bind their cognate
receptors on hepatocytes and antigen presenting cells in the liver,
they upregulate hundreds of ISGs with potent endogenous anti-
HCV activity through activation of the Jak-STAT signaling
pathway and likely convergence with the type I IFN (IFNa and b)
pathway. [19,35]
An interplay between variable activation of these host
endogenous interferon pathways and multiple viral resistance
mechanisms, such as amino acid substitutions at positions 70 and
91 of the HCV core protein, accumulation of substitutions in the
interferon sensitivity regions (ISDR) of the NS5A protein, and viral
recruitment of liver-specific micro RNA (miR-122) to enhance its
abundance, may functionally determine the pretreatment HCV
viral population and its potential response to exogenous interferon
administration.[36,37,38,39,40] These host and viral factors have
been shown to be independent in predicting HCV treatment
outcomes [22,23,33], and as such, can explain why both the IL28B
genotype and baseline HCV viral load emerged in our study as
strong and independent predictors of PEG/WBR response.
A simple genetic test for the rs12979860 genotype is now
commercially available in the United State. [41] However, as
shown by us and others, IL28B genotype is not perfect in
predicting treatment outcomes or completely precluding subjects
homozygous for the non-responder alleles from achieving SVR.
This is likely due to the complexity of viral-host interactions and
variable expression of ISGs even among subjects with favorable
IL28B genotypes. [31] To that end, we have developed a
prediction score capitalizing on the negative predictive value of
two strong and consistently reported predictors of HCV treatment
outcomes (IL28B genotype and baseline HCV viral load).
This simple pretreatment prediction score enabled us to achieve
a high negative predictive value for SVR (93%) in this difficult to
treat HCV/HIV coinfected cohort. If applied to the SLAM-C
cohort prior to HCV therapy, it would have identified 67 subjects
with unfavorable pretreatment scores (#3 points) and minimized
their unnecessary exposure to potentially harmful therapy.
Furthermore, 58 SLAM-C subjects had less favorable IL28B
genotypes but low baseline HCV viral load enabling them to
achieve a favorable pretreatment prediction score (.3 points),
Table 4. Genotype distribution of the three IL28B SNPs in
each ethnic group.
White (103) Black (80) Hispanic (38)
rs12979860
TT 11% 28% 21%
CT 44% 55% 53%
CC 45% 17% 26%
rs8099917
GG 6% 1% 13%
TG 30% 21% 37%
TT 64% 78% 50%
rs12980275
GG 8% 20% 18%
AG 46% 49% 50%
AA 46% 31% 32%
doi:10.1371/journal.pone.0025753.t004
Table 5. Association between black race and SVR unadjusted and adjusted for rs12979860.
Black vs. White Unadjusted
Black vs. White Adjusted for
rs12979860 Percent Change in OR
SVR 0.5 [0.26–0.97] 0.68 [0.33–1.4] 36%
doi:10.1371/journal.pone.0025753.t005
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predictor of their HCV treatment outcome to justify excluding
them from therapy based on this measure alone (Figure 3).
Medrano and colleagues have previously derived and validated
a prediction score for achieving SVR in predominantly white
HCV/HIV coinfected cohort from Spain [28]. The variable
included in their prediction score were IL28B genotype
rs12979860 (CT or TT vs. CC), liver stiffness assessed by transient
elastography (FirboScan), HCV genotype (1 and 4 vs. 2 and 3),
and baseline HCV viral load. Their prediction score had a higher
area under the ROC than ours (0.892 vs. 0.78). However, this was
likely secondary to having a predominantly white cohort, inclusion
of HCV genotype as a predictor of outcome, and the inclusion of
subjects who only completed a full course of therapy with
documented outcomes. Nonetheless, their finding complements
our by confirming the importance of IL28B genotype and baseline
HCV viral load as independent predictors of HCV treatment
outcomes.
The strengths of our study include its relatively large sample
size, prospective design and outcome ascertainment in the context
Figure 2. Area under ROC for predicting SVR from a model including IL28B genotype (rs12979860) and baseline HCV viral load.
doi:10.1371/journal.pone.0025753.g002
Table 6. Prediction score for complete EVR and SVR.
Predictor Points Cut-off Point Negative Predictive Value (NPV)
rs12979860 #3 points 88% for cEVR
93% for SVR
N TT 0
N CT 3
N CC 6
HCV RNA IU/mL (base-line)
N .5,000,000 0
N 500,000–5,000,000 3
N ,500,000 6
Maximum points 12 .3 points Indeterminate
doi:10.1371/journal.pone.0025753.t006
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Several limitations deserve comment. First, SVR was assessed after
72 weeks of therapy. This can be viewed as strength rather than a
weakness, since extending the treatment duration would have
likely minimized false negative outcomes given the emphasis on
the negative predictive value for SVR in our prediction score.
Second, about a third of the cohort was interferon experienced.
However, this should have had little influence on retreatment
outcomes as related to IL28B polymorphisms. Furthermore, our
derived score predicted null virologic response, an outcome
unlikely to change with repeat PEG/WBR treatment. Third, we
lacked an appropriate validation cohort to validate our prediction
score; thus, appropriate validation is needed before incorporating
this score in clinical HCV treatment algorithms. Finally, it is
unclear how information about IL28B gene polymorphisms will
incorporated in HCV/HIV treatment algorithms in the era of
direct-acting antiviral (DAA) therapy for HCV; it could be that it
would assist triaging patients to conventional vs. DAA therapy to
minimize risk for development of DAA resistance.
In conclusion, we have shown that SNPs in regions surrounding
the IL28B gene are associated with PEG/RBV treatment
outcomes in a prospective study of HCV/HIV coinfected persons.
These alleles have an additive dose effect and explain some of the
racial differences in HCV treatment outcomes between blacks and
whites. An HCV pretreatment prediction score that found a high
negative predictive value for the IL28B non-responder homozy-
gote genotype and high baseline HCV viral load, was able to
identify a significant number of coinfected subjects with very low
pretreatment likelihood to respond to peg-IFN and RBV. Future
approaches to integrate a simple prediction model into the HCV-
HIV coinfection management would appear to be warranted to
limit potentially harmful exposure to this vulnerable population.
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